The molecular pathogenesis of corticotroph tumours

European Journal of Clinical Investigation

Volumn 42, Issue 6, 2012, Pages 665-676

  Dworakowska, Dorota ^a,b,c   Grossman, Ashley B ^c,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Corticotroph adenoma; Molecular alteration; Molecular pathogenesis; Pathophysiology

Indexed keywords

BETA CATENIN; CADHERIN; CORTICOTROPIN; HYDROCORTISONE; INTEGRIN;

ACTH SECRETING ADENOMA; ADRENAL TUMOR; ALBRIGHT SYNDROME; CARCINOGENESIS; CARNEY COMPLEX; CELL CONTACT; CUSHING DISEASE; DISEASE PREDISPOSITION; GENETIC ASSOCIATION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; MOLECULAR PATHOLOGY; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TUBEROUS SCLEROSIS;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; CORTICOTROPHS; HUMANS; PITUITARY ACTH HYPERSECRETION; SIGNAL TRANSDUCTION;

EID: 84860920247     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02621.x     Document Type: Review

References (109)

1. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 2006;59:341-53; discussion 41-53.
2. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613-9.
3. Daly AF, Burlacu MC, Livadariu E, Beckers A. The epidemiology and management of pituitary incidentalomas. Horm Res 2007;68(Suppl 5):195-8.
4. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010;72:377-82.
5. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U et al. Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001;86:117-23.
6. Levy A. Molecular and trophic mechanisms of tumorigenesis. Endocrinol Metab Clin North Am 2008;37:23-50, vii.
7. Pinchot SN, Sippel R, Chen H. ACTH-producing carcinoma of the pituitary with refractory Cushing's Disease and hepatic metastases: a case report and review of the literature. World J Surg Oncol 2009;7:39.
8. Bertagna X, Guignat L, Groussin L, Bertherat J. Cushing's disease. Best Pract Res Clin Endocrinol Metab 2009;23:607-23.
9. Stewart PM, Petersenn S. Rationale for treatment and therapeutic options in Cushing's disease. Best Pract Res Clin Endocrinol Metab 2009;23(Suppl 1):S15-22.
10. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011;7:257-66.
11. Dahia PL, Grossman AB. The molecular pathogenesis of corticotroph tumors. Endocr Rev 1999;20:136-55.
12. Alexander JM, Biller BM, Bikkal H, Zervas NT, Arnold A, Klibanski A. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990;86:336-40.
13. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990;71:1427-33.
14. Melmed S. Pituitary neoplasia. Endocrinol Metab Clin North Am 1994;23:81-92.
15. Boikos SA, Stratakis CA. Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Hum Mol Genet 2007;16:R80-7.
16. Karhu A, Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Hum Mol Genet 2007;1:R73-9.
17. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006;103:15558-63.
18. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006;312:1228-30.
19. Igreja S, Chahal HS, Akker SA, Gueorguiev M, Popovic V, Damjanovic S et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol (Oxf) 2009;70:259-64.
20. Riminucci M, Collins MT, Lala R, Corsi A, Matarazzo P, Gehron Robey P et al. An R201H activating mutation of the GNAS1 (Gsalpha) gene in a corticotroph pituitary adenoma. Mol Pathol 2002;55:58-60.
21. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D et al. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 2002;87:5104-12.
22. Cuttler L, Jackson JA, Saeed uz-Zafar M, Levitsky LL, Mellinger RC, Frohman LA. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab 1989;68:1148-54.
23. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 1990;71:1421-6.
24. Lania A, Mantovani G, Spada A. Genetics of pituitary tumors: focus on G-protein mutations. Exp Biol Med (Maywood) 2003;228:1004-17.
25. Stratakis CA, Tichomirowa MA, Boikos S, Azevedo MF, Lodish M, Martari M et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 2010;78:457-63.
26. Burgess JR, Greenaway TM, Shepherd JJ. Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 1998;243:465-70.
27. Jagannathan J, Dumont AS, Prevedello DM, Lopes B, Oskouian RJ, Jane JA Jr et al. Genetics of pituitary adenomas: current theories and future implications. Neurosurg Focus 2005;19:E4.
28. Rix M, Hertel NT, Nielsen FC, Jacobsen BB, Hoejberg AS, Brixen K et al. Cushing's disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur J Endocrinol 2004;151:709-15.
29. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007;92:3321-5.
30. Dahia PL, Aguiar RC, Honegger J, Fahlbush R, Jordan S, Lowe DG et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 1998;16:69-76.
31. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
32. Bossis I, Voutetakis A, Matyakhina L, Pack S, Abu-Asab M, Bourdeau I et al. A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus. J Med Genet 2004;41:596-600.
33. Kaltsas GA, Kola B, Borboli N, Morris DG, Gueorguiev M, Swords FM et al. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin Endocrinol (Oxf) 2002;57:443-8.
34. Yaneva M, Vandeva S, Zacharieva S, Daly AF, Beckers A. Genetics of Cushing's syndrome. Neuroendocrinology 2010;92(Suppl 1):6-10.
35. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006;91:3316-23.
36. Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Makinen MJ, Vierimaa O et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci U S A 2007;104:4101-5.
37. Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 2007;157:371-82.
38. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007;92:1891-6.
39. Gadelha MR, Une KN, Rohde K, Vaisman M, Kineman RD, Frohman LA. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J Clin Endocrinol Metab 2000;85:707-14.
40. Georgitsi M, Heliovaara E, Paschke R, Kumar AV, Tischkowitz M, Vierimaa O et al. Large genomic deletions in AIP in pituitary adenoma predisposition. J Clin Endocrinol Metab 2008;93:4146-51.
41. Dworakowska D, Grossman AB. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr Relat Cancer 2009;16:45-58.
42. Tigas S, Carroll PV, Jones R, Bingham E, Russell-Jones D, Powell M et al. Simultaneous Cushing's disease and tuberous sclerosis; a potential role for TSC in pituitary ontogeny. Clin Endocrinol (Oxf) 2005;63:694-5.
43. Nandagopal R, Vortmeyer A, Oldfield EH, Keil MF, Stratakis CA. Cushing's syndrome due to a pituitary corticotropinoma in a child with tuberous sclerosis: an association or a coincidence? Clin Endocrinol (Oxf) 2007;67:639-41.
44. de Keyzer Y, Rene P, Beldjord C, Lenne F, Bertagna X. Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clin Endocrinol (Oxf) 1998;49:475-82.
45. Dieterich KD, Gundelfinger ED, Ludecke DK, Lehnert H. Mutation and expression analysis of corticotropin-releasing factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1998;83:3327-31.
46. Morris DG, Kola B, Borboli N, Kaltsas GA, Gueorguiev M, McNicol AM et al. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. J Clin Endocrinol Metab 2003;88:6080-7.
47. Briassoulis G, Damjanovic S, Xekouki P, Lefebvre H, Stratakis CA. The glucocorticoid receptor and its expression in anterior pituitary and the adrenal cortex: a source of variation in hypothalamic-pituitary-adrenal axis function; implications for pituitary and adrenal tumors. Endocr Pract 2011;8:1-27.
48. Ebisawa T, Tojo K, Tajima N, Kamio M, Oki Y, Ono K et al. Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma. Endocr Pathol 2008;19:252-60.
49. Dahia PL, Honegger J, Reincke M, Jacobs RA, Mirtella A, Fahlbusch R et al. Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumors. J Clin Endocrinol Metab 1997;82:1088-93.
50. Karl M, Von Wichert G, Kempter E, Katz DA, Reincke M, Monig H et al. Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 1996;81:124-9.
51. Dahia PL, Ahmed-Shuaib A, Jacobs RA, Chew SL, Honegger J, Fahlbusch R et al. Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. J Clin Endocrinol Metab 1996;81:1768-71.
52. Korbonits M, Bujalska I, Shimojo M, Nobes J, Jordan S, Grossman AB et al. Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. J Clin Endocrinol Metab 2001;86:2728-33.
53. Rabbitt EH, Ayuk J, Boelaert K, Sheppard MC, Hewison M, Stewart PM et al. Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene 2003;22:1663-7.
54. Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006;20:2871-86.
55. Drouin J, Bilodeau S, Vallette S. Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency. Clin Genet 2007;72:175-82.
56. Roussel-Gervais A, Bilodeau S, Vallette S, Berthelet F, Lacroix A, Figarella-Branger D et al. Cooperation between Cyclin E and p27(Kip1) in pituitary tumorigenesis. Mol Endocrinol 2010;24:1835-45.
57. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 2000;143:R1-6.
58. Giacomini D, Acuna M, Gerez J, Nagashima AC, Silberstein S, Paez-Pereda M et al. Pituitary action of cytokines: focus on BMP-4 and gp130 family. Neuroendocrinology 2007;85:94-100.
59. Pereda MP, Lohrer P, Kovalovsky D, Perez Castro C, Goldberg V, Losa M et al. Interleukin-6 is inhibited by glucocorticoids and stimulates ACTH secretion and POMC expression in human corticotroph pituitary adenomas. Exp Clin Endocrinol Diabetes 2000;108:202-7.
60. Tsagarakis S, Kontogeorgos G, Giannou P, Thalassinos N, Woolley J, Besser GM et al. Interleukin-6, a growth promoting cytokine, is present in human pituitary adenomas: an immunocytochemical study. Clin Endocrinol (Oxf) 1992;37:163-7.
61. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:881-7.
62. Korbonits M, Kojima M, Kangawa K, Grossman AB. Presence of ghrelin in normal and adenomatous human pituitary. Endocrine 2001;14:101-4.
63. Nanzer AM, Khalaf S, Mozid AM, Fowkes RC, Patel MV, Burrin JM et al. Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. Eur J Endocrinol 2004;151:233-40.
64. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 2005;23:5386-403.
65. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997;89:457-67.
66. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997;385:544-8.
67. Volarevic S, Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 2001;65:101-27.
68. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-57.
69. Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998;10:268-75.
70. Rosenwald IB, Kaspar R, Rousseau D, Gehrke L, Leboulch P, Chen JJ et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995;270:21176-80.
71. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 2005;12:423-33.
72. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 2009;16:1329-38.
73. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN et al. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res 1999;5:2133-9.
74. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 2002;87:2635-43.
75. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer 2002;2:836-49.
76. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL. Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 1992;74:914-9.
77. Herman V, Drazin NZ, Gonsky R, Melmed S. Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 1993;77:50-5.
78. Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, McTernan P et al. Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab 1994;78:387-92.
79. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997;11:433-41.
80. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Relat Cancer 2008;15:721-43.
81. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999;285:418-22.
82. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999;84:761-7.
83. Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J Biol Chem 2000;275:7459-61.
84. Chamaon K, Kirches E, Kanakis D, Braeuninger S, Dietzmann K, Mawrin C. Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes. Biochem Biophys Res Commun 2005;331:86-92.
85. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 2006;65:536-43.
86. Salehi F, Kovacs K, Scheithauer BW, Cantelmi D, Horvath E, Lloyd RV et al. Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. Int J Surg Pathol 2010;18:5-13.
87. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-97.
88. Givol D, Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992;6:3362-9.
89. Ezzat S, Smyth HS, Ramyar L, Asa SL. Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. J Clin Endocrinol Metab 1995;80:878-84.
90. Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T et al. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 2004;89:1904-11.
91. Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C et al. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 2005;64:398-403.
92. Yoshino A, Katayama Y, Ogino A, Watanabe T, Yachi K, Ohta T et al. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas. J Neurooncol 2007;83:153-62.
93. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 1997;150:401-7.
94. Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999;84:3823-30.
95. Bellodi C, Krasnykh O, Haynes N, Theodoropoulou M, Peng G, Montanaro L et al. Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res 2010;70:6026-35.
96. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 2001;86:3097-107.
97. Morris DG, Musat M, Czirjak S, Hanzely Z, Lillington DM, Korbonits M et al. Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol 2005;153:143-51.
98. Hofland LJ, Lamberts SW, Feelders RA. Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells. Neuroendocrinology 2010;92(Suppl 1):11-6.
99. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009;94:115-22.
100. van der Hoek J, Lamberts SW, Hofland LJ. The somatostatin receptor subtype 5 in neuroendocrine tumours. Expert Opin Investig Drugs 2010;19:385-99.
101. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J 2009;56:579-84.
102. Pedroncelli AM. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide. Neuroendocrinology 2010;92(Suppl 1):120-4.
103. Tani Y, Inoshita N, Sugiyama T, Kato M, Yamada S, Shichiri M et al. Upregulation of CDKN2A and suppression of cyclin D1 gene expressions in ACTH-secreting pituitary adenomas. Eur J Endocrinol 2010;163:523-9.
104. Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J et al. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol 2010;163:35-43.
105. Woo YS, Isidori AM, Wat WZ, Kaltsas GA, Afshar F, Sabin I et al. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005;90:4963-9.
106. Mustila T, Keskinen P, Terho M, Huovinen S, Saha MT. Pediatric Cushing's disease due to pituitary hyperplasia. J Pediatr Endocrinol Metab 2011;24:191-2.
107. Benoit I, Drui D, Chaillous L, Dupas B, Mosnier JF, Charbonnel B et al. A corticotroph pituitary adenoma as the initial presentation of familial glucocorticoid deficiency. Eur J Endocrinol 2009;161:195-9.
108. Haap M, Gallwitz B, Meyermann R, Mittelbronn M. Cushing's disease associated with both pituitary microadenoma and corticotroph hyperplasia. Exp Clin Endocrinol Diabetes 2009;117:289-93.
109. Kovacs K, Horvath E, Coire C, Cusimano M, Smyth H, Scheithauer BW et al. Pituitary corticotroph hyperplasia preceding adenoma in a patient with Nelson's syndrome. Clin Neuropathol 2006;25:74-80.